HQP1351 was used in a phase I recruiting clinical trial with patients with GIST [86], PLX9486 is a TKR inhibitor, and was used with or without sunitinib in patients with advanced solid tumors and GIST, a completed clinical trial without any results known [87]. Here, TKTL1 is linked to gastrointestinal stromal tumor.